A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma.

Trial Profile

A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Olaparib (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms OPARATIC
  • Most Recent Events

    • 01 Feb 2018 Status changed to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top